MergerLinks Daily Review

MergerLinks Daily Review

Welcome to MergerLinks Daily Review.?Sign up here?to get the full round up of your daily dose of blue-chip M&A news directly to your inbox.

Musk’s legal team hits former Twitter boss Dorsey with subpoena as legal fight over $44bn deal continues.

Alcon to acquire Aerie Pharmaceuticals for $770m.

Qatar Investment Authority led a $400m Series D round in Celonis. (Financial Sponsors)

Intel signs $30bn funding partnership with Brookfield to finance chip-factory expansion. (FS)

Olympus nearing deal to sell microscope unit for over $2bn. (FS)

You can access today’s complete newsletter?here.

Scroll down for more…

Brak alternatywnego tekstu dla tego zdj?cia

Musk’s legal team hits former Twitter boss Dorsey with subpoena as legal fight over $44bn deal continues.

Elon Musk’s lawyers have sent a subpoena to Jack Dorsey, the first indication that Twitter’s co-founder and former chief executive will be officially involved in the legal fight over Musk’s stalled $44bn deal.

Musk is seeking documents from Dorsey relating to the effect of false or spam accounts on the social media platform’s business.

Brak alternatywnego tekstu dla tego zdj?cia

Alcon to acquire Aerie Pharmaceuticals for $770m.

Alcon, an American Swiss medical company specializing in eye care products, agreed to acquire Aerie Pharmaceuticals, a pharmaceutical company focused on the discovery, development, manufacturing and commercialization of first-in-class ophthalmic therapies, for $770m.

"Alcon is passionate about innovative treatments in eye care, especially in core disorders such as glaucoma and dry eye, which have significant patient impact. We have a 75-year history focused specifically on the eye and bring established expertise in development and commercial execution. Aerie is a natural fit with on-market and pipeline products, and R&D capabilities that offer the infrastructure needed to expand our ophthalmic pharmaceutical presence. As we continue to broaden our portfolio across glaucoma, retina and ocular surface disease, we are excited to help even more patients see brilliantly," David Endicott, Alcon CEO.

Aerie Pharmaceuticals is advised by Goldman Sachs and Fried Frank Harris Shriver & Jacobson. Alcon is advised by JP Morgan and Skadden Arps Slate Meagher & Flom.

Brak alternatywnego tekstu dla tego zdj?cia

Qatar Investment Authority led a $400m Series D round in Celonis. (FS)

Qatar Investment Authority, a sovereign wealth fund, led a $400m Series D round in Celonis, a data processing company, with participation from Activant Capital, Neuberger Berman, Alta Park Capital, Commonfund Capital, Arena, T. Rowe Price Associates, Franklin Templeton, Durable Capital Partners, TCV, 83North, Accel Partners and Sator Grove.

"Since the first days of Celonis, we have built a company that is operating on sound fundamentals, immutable customer value and the kind of resiliency that performs at the highest levels in any economic environment. These fundamentals are what put Celonis in such a unique position to lean into the wind, while others are stepping back. With an additional $1bn in liquidity, Celonis will have maximum flexibility to aggressively innovate, capitalize on new market opportunities and extend our market leadership," Bastian Nominacher, Celonis Co-CEO and Co-Founder.

Brak alternatywnego tekstu dla tego zdj?cia

Intel signs $30bn funding partnership with Brookfield to finance chip-factory expansion. (FS)

Intel has struck an unusual $30bn funding partnership with Brookfield Asset Management to help finance its massive factory expansion ambitions, signaling some big investors are upbeat about the long-term demand for semiconductors,?WSJ?reported.

The agreement with the publicly traded Canadian asset-management firm is the first of what could be a series of such arrangements Intel pursues to underpin Chief Executive Pat Gelsinger’s push to make the company a leading contract chip maker and regain its manufacturing advantage over competitors in Taiwan and South Korea.

Brak alternatywnego tekstu dla tego zdj?cia

Olympus nearing deal to sell microscope unit for over $2bn. (FS)

Japan’s Olympus is close to selling its microscope unit to a private equity firm in a deal that could fetch more than $2.2bn.

Bain Capital has emerged as the frontrunner. Carlyle Group and KKR also submitted binding bids this month for the unit which makes microscopes, industrial endoscopes and x-ray analysers.

Interested to find more??Sign up here?to get full round up of your daily dose of blue-chip M&A news directly to your inbox.

You can access today’s complete newsletter?here.

要查看或添加评论,请登录

MergerLinks的更多文章

社区洞察

其他会员也浏览了